Therapeutic Uses of Selincro 18 mg

What Selincro Treats: Main Uses and Benefits

Selincro is commonly used to help with a patient's goal of reducing their drinking rather than achieving immediate total abstinence, relevant in conditions characterized by periods of heightened symptoms related to alcohol use disorder. This targeted approach plays a role in managing the core symptoms and high-risk behaviors associated with sustained alcohol consumption.

The medication is commonly used to help with addressing intense psychological symptom domains, including the compulsive urge and craving that drives consumption. The primary therapeutic benefit may be part of symptomatic management to achieve a reduction in the quantity of alcohol consumed, which may assist with lowering the overall health risk. The primary clinical indications for Selincro include treatment for alcohol dependence in adults, and the management of high drinking risk levels.

It may be part of a harm reduction strategy, applied within a comprehensive treatment framework. By easing the intensity of the urge, the therapy may provide support that helps ease the overall symptom burden and assists with maintaining functional stability.

Quick Fact: Therapeutic Domains

Supportive Relief for Compulsive Alcohol Craving and High Drinking Risk Levels.
Assists with managing symptoms that interfere with daily comfort and contributes to easing the overall symptom load related to the psychological drive to drink.

Regulatory References

European Medicines Agency's therapeutic overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Selincro 18 mg?

This section outlines the official eligibility and exclusion criteria for Selincro (nalmefene), as defined by regulatory documents.

Contraindications (Must Not Use)

Selincro is strictly contraindicated for individuals who:

Are currently taking opioid agonists (including certain strong pain relievers, methadone, or buprenorphine), have a current or recent opioid addiction, or are experiencing acute opioid withdrawal.
Have severe hepatic impairment (liver disease) or severe renal impairment (kidney disease, defined as eGFR < 30 ml/min per 1.73 m^2).
Have a recent history of acute alcohol withdrawal syndrome (such as seizures or delirium tremens).
Have a known hypersensitivity to nalmefene or any excipients.

Restricted and Special Populations

Population	Regulatory Status
Age	Only indicated for adults (18 years and older); use is not established in the paediatric population.
Pregnancy	Not recommended due to limited data.
Breastfeeding	Caution is required; a decision must be made to discontinue nursing or therapy.
Elderly (ge 65)	Use with caution due to limited clinical data.
Mild/Moderate Impairment	Use with caution in patients with mild or moderate hepatic or renal impairment.

These criteria define the mandatory clinical and physiological boundaries for treatment eligibility.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information strictly defines the interaction profile of Nalmefene, primarily concerning its activity as an opioid system modulator and its metabolism.

Classification	Interaction Entity / Restriction
Contraindicated Combination	Opioid Agonists (e.g., opioid analgesics, methadone, buprenorphine). Co-administration is prohibited due to the risk of precipitated opioid withdrawal symptoms or complete blockade of the opioid's effect.
Timing-based Rule	Opioids: Nalmefene must be temporarily discontinued for 1 week prior to the anticipated need for continuous opioid use, such as for elective surgery.

Interactions involving liver enzyme pathways are also documented:

Metabolic Interactions: Nalmefene is primarily metabolized by the UGT2B7 enzyme. Co-administration with potent UGT2B7 inhibitors (e.g., fluconazole, diclofenac) may significantly increase Nalmefene exposure. Conversely, UGT inducers (e.g., rifampicin, omeprazole) may potentially lead to subtherapeutic plasma concentrations.
Population-Specific Note: Nalmefene oral clearance is documented to be reduced by up to 60% in patients with moderate hepatic impairment, resulting in a substantial increase in drug exposure (AUC).

No clinically relevant pharmacokinetic drug-drug interaction is documented between Nalmefene and alcohol, although simultaneous intake does not prevent the intoxicating effects of alcohol. Furthermore, no clinically relevant interactions involving membrane transporters are anticipated.

Mechanism of Action

Selective Opioid Receptor Modulation

The active molecule is concentrated within the Central Nervous System to affect key neural circuits that influence reinforcement signaling. It acts as an Opioid System Modulator by selectively binding to and blocking the mu- and delta-opioid receptors, while demonstrating Partial Agonism at the kappa-opioid receptor. This multi-receptor profile directly influences the signaling dynamics of the Endogenous Opioid System in the Central Nervous System.

Disruption of the Mesolimbic Reward Cascade

This receptor modulation initiates a cascade that disrupts the Mesolimbic Pathway (the reward circuit). By preventing the activation of mu- and delta-opioid receptors, the molecule limits the surge of dopamine release in the Nucleus Accumbens that typically occurs as part of the neurological reinforcement loop. By limiting this signaling cascade, the molecule reduces the functional intensity of the reinforcement signal.

Functional Boundary of Action

The mechanism is primarily focused on modulating the reward axis. It does not directly influence the separate GABA/Glutamate systems and is therefore physiologically constrained from modulating the specific neural pathways involved in acute physical withdrawal.

Dosage and Administration Information

How to Use Selincro 18 mg

The usage of Selincro 18 mg is guided by specific instructions detailed in prescribing information, establishing a contingent-use oral therapy.

Official Administration Guidelines

Administration Scope	Official Instruction
Route of Administration	The medicine is taken for oral use; the tablet must be swallowed whole.
Dosing Schedule	A fixed dose of one 18 mg film-coated tablet. The maximum dose is limited to one tablet per day.
Frequency Pattern	Administered on an as-needed basis, taken only on days when the patient perceives a risk of drinking alcohol.
Timing Requirements	The dose should preferably be taken 1 to 2 hours prior to the anticipated time of drinking. It may be taken with or without food.
Missed Dose Rule	If drinking has started without the tablet being taken, one tablet should be taken as soon as possible.

Procedural Context and Constraints

Procedural Structure: The medicine is designed to be used by the patient before a high-risk drinking episode. The tablet must not be divided or crushed and must be swallowed whole to ensure proper administration.

Special Conditions: The therapy is intended for use in conjunction with continuous psychosocial support and counselling focused on adherence and achieving a reduction in alcohol consumption. The protocol requires that patients be assessed for at least two weeks before treatment begins to confirm a persistently high drinking risk level. No dose adjustment is recommended for older adults or those with mild to moderate renal or hepatic impairment.

Recent Clinical Evidence

Research evidence / Overview of studies for Selincro 18 mg

Evidence for use in Adult Alcohol Dependence with High Drinking Risk

This section will summarize the core research base for Nalmefene, focusing on the pivotal Randomized Controlled Trials (RCTs) and meta-analyses that examined its use in adults with alcohol dependence who were identified as having a high risk level for consumption.

Research for Selincro was evaluated in adults experiencing alcohol dependence, a condition characterized by fluctuating or episodic manifestations. Studies explored its use in people who were already seeking help and participating in psychosocial support programs. The main evidence comes from intermediate-term Randomized Controlled Trials (RCTs), which included participants observed over several months. These trials compared the outcomes of patients receiving Nalmefene plus counseling with those receiving a placebo (an inactive treatment) plus the same counseling.

Research describes changes measured during the study period, particularly in the subgroup of patients who were identified as having a high drinking risk at the start of the study. Measurements of outcomes related to systemic or functional imbalance were observed in these studies. The specific population studied was defined using a re-analysis of the original trial data.

Measures of Change Studied in Clinical Trials

This part will detail the specific outcomes that researchers primarily evaluated in the studies, such as the change in the Number of Heavy Drinking Days and the change in Total Alcohol Consumption over the intermediate duration of the trials.

Researchers mainly examined two specific measurements: the change in the Number of Heavy Drinking Days (HDD) per month and the change in Total Alcohol Consumption (TAC), measured in daily grams of alcohol. These are the primary outcomes reflecting daily functioning or activity level that were monitored across the studies. Studies also explored outcomes related to physical discomfort by monitoring certain liver enzyme levels, and Secondary outcomes related to liver enzymes and the Clinical Global Impression (CGI) assessment were also monitored.

Findings describe group patterns related to the changes measured during the study period for HDD and TAC in the observed populations. However, these two measures are considered surrogate measures of health. Therefore, the evidence helps contextualize how patients reported their experience and how symptoms evolved, but it does not determine the impact on hard outcomes like long-term physical health or mortality.

Long-term Studies and Extended Follow-up

This section will summarize what is known about the durability of the observed patterns over time, detailing the available data from extended duration studies and follow-up periods beyond the initial six months.

The initial pivotal RCTs monitored responses over a defined time interval of about six months. Studies observed patterns where measured changes continued through the duration of these specific trials, though evidence for longer time frames is limited.

Long-term effects are not fully established. Follow-up durations were limited for many participants, and certainty remains low regarding outcomes after the initial intermediate-term study period. Research is ongoing, but there is limited information for long-term outcomes, and the available data for extended follow-up often comes from observational settings, where evidence quality varies across studies.

Evidence in Specific Patient Groups

This segment will outline what studies have evaluated specific populations, such as older adults, or those with certain pre-existing conditions, highlighting groups that were excluded from the pivotal trials and where evidence remains limited.

The studies were conducted on a carefully selected population of adults. Results apply only to the populations studied in the trials, which means data for certain groups remain insufficient.

For instance, the trials specifically excluded patients with significant health issues, such as severe liver or kidney problems, or certain unstable psychiatric conditions. Consequently, data for these certain groups remain insufficient. The evidence describes what is known for the population studied, but research also explores what is still uncertain when it comes to individuals with complex comorbid conditions. Comparative evidence is lacking for how Nalmefene was associated with outcomes in these special populations.

What is Still Uncertain About the Research Evidence

This final part will synthesize the main evidence gaps, inconsistent findings, and the limitations noted by regulators and systematic reviews, including the reliance on surrogate endpoints and the generalizability of results.

A number of research limitation frames have been noted in the evidence landscape for Selincro. One limitation is that the trials saw a high percentage of patients who chose to withdraw early. This contributes to uncertainty regarding long-term outcomes and the sustained changes over time. Additionally, the primary outcomes used (HDD and TAC) are behavioral measures, and their link to substantial, long-term health improvements is not fully established.

The research describes short-term changes for the studied population, but certainty remains low for extended outcomes. Subgroup findings are uncertain, and results apply only to the populations studied under the specific conditions of the RCTs. The research does not determine whether an individual will respond similarly, and data for long-term effects remain limited.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Selincro 18 mg (FAQ)

Q: Is Selincro 18 mg a cure for alcohol dependence?

Official regulatory documents state that Selincro is indicated for the reduction of alcohol consumption in adults who are alcohol dependent. It is not intended for patients whose immediate treatment goal is complete abstinence, but rather for those seeking a measurable reduction in the amount of alcohol they consume.

Q: Is Selincro 18 mg the same as Antabuse or other similar drugs?

Selincro’s active substance, nalmefene, is classified as an opioid system modulator because it acts on specific brain receptors to lessen the rewarding effects of alcohol. This is a different approach from other medicines used for alcohol-related conditions, such as disulfiram (Antabuse), which works by creating an unpleasant physical reaction to alcohol.

Q: How long after starting Selincro 18 mg should I expect to see effects?

Official administration guidelines state the tablet is taken 1 to 2 hours prior to an anticipated drinking episode for its pharmacological action to begin. In clinical trials, the greatest improvement in measured drinking outcomes was typically observed within the first month (4 weeks) of initiating treatment.

Q: Are there any major food restrictions when taking Selincro?

Official product information confirms that Selincro can be taken with or without food. There are no major food restrictions noted in the regulatory documents for the use of this medicine.

Q: Does Selincro 18 mg cause weight gain?

In clinical trials, some patients experienced decreased appetite, which is listed as a common side effect of the medicine. Regulatory data also noted a decrease in measured weight in some patients, rather than weight gain.

Q: Can I take Selincro 18 mg if I'm already taking antidepressants?

Regulatory information indicates that no clinically relevant interactions are anticipated between nalmefene and most common medications that are processed by the CYP450 and UGT enzyme systems. Specific antidepressant classes are not listed as mandatory contraindications in the official documentation. The full list of medicines should be reviewed by a prescribing healthcare provider.

Q: What common painkillers should I avoid while on Selincro?

Selincro is strictly contraindicated if a person is currently taking medications containing opioid agonists, such as certain opioid analgesics (strong pain relievers like morphine or oxycodone) or methadone. Regulatory information states that this combination is prohibited due to the risk of precipitated opioid withdrawal symptoms.

Q: Is it safe to drive or operate machinery while taking Selincro 18 mg?

Official product information states that Selincro may have a minor to moderate influence on the ability to drive or use machines. The official label advises that caution is required, particularly when starting treatment, due to common side effects including dizziness, somnolence (drowsiness), and disturbance in attention.

Q: How is Selincro 18 mg different from Naltrexone?

The active substance, nalmefene, is structurally related to naltrexone but is recognized for having unique pharmacological properties. Nalmefene is specifically distinguished by its action as a partial agonist at the kappa-opioid receptor, which gives it a different activity profile compared to naltrexone.

Q: Why is Selincro 18 mg prescribed for 'reduction' rather than 'abstinence'?

The therapeutic indication for Selincro is specifically to support the reduction of alcohol consumption. Regulatory documents clarify that it is not intended for use in patients whose treatment goal is immediate and complete abstinence from alcohol.

Q: Is Selincro 18 mg addictive?

Regulatory overviews confirm that nalmefene has no opioid agonist activity and is not associated with drug tolerance, physical dependence, or abuse potential.

Q: How long can a person stay on Selincro 18 mg?

Clinical trial data from randomized controlled studies are available for periods of 6 to 12 months. Official guidelines advise that caution is used if the medicine is prescribed for longer than 1 year, as long-term effects beyond this duration are not fully established.

Q: Can Selincro 18 mg be used by people with high blood pressure?

High blood pressure is not listed as a specific contraindication for Selincro. However, official regulatory documents list tachycardia (fast heart rate) and palpitations as common side effects that can occur in some people.

Q: What age group has been studied the most for Selincro use?

Selincro is indicated exclusively for adults aged 18 years and older. Safety and efficacy have not been formally established in the pediatric population. The clinical trials were conducted on a selected population of adults seeking help for alcohol dependence.

Q: Is Selincro 18 mg available in countries outside of Europe?

The oral tablet formulation of Selincro has been approved by regulatory bodies in Europe (EMA) and Australia (TGA). However, the oral tablet is not approved by the FDA for the treatment of alcohol dependence in the United States.

Q: Are there any known long-term side effects of Selincro 18 mg?

The controlled clinical data for Selincro extends to a period of 6 to 12 months. Regulatory documents advise that long-term effects beyond one year are not fully established, and caution is advised if treatment is extended past that timeframe.

Q: Does Selincro 18 mg have an effect on cravings generally?

Nalmefene is described as working by modifying the brain’s opioid system, which directly influences the neurological reward pathways linked to alcohol consumption. This action helps to reduce the urge to drink in patients who typically consume large amounts of alcohol.

Q: Can men and women expect different outcomes from taking Selincro 18 mg?

Clinical studies included both men and women and reported overall group results related to changes in alcohol consumption. Official indications reflect different physiological risk thresholds for men and women when defining high drinking risk, but do not specify differences in outcome patterns based on sex.

Q: Are there alternative uses for the active ingredient in Selincro?

The active substance in Selincro, nalmefene, is also approved by various regulators in other formulations (such as injection or nasal spray) for the reversal of opioid drug effects and the emergency management of known or suspected opioid overdose.

Q: What is the experience of most patients using Selincro?

The most commonly reported effects in clinical trials are nausea, dizziness, insomnia, and headache. Regulatory safety information notes that these common adverse reactions are typically mild to moderate in severity and tend to be transient, occurring early in the course of treatment.

Q: Are there any known interactions between Selincro and common cold medicines?

Regulatory guidelines state that individuals must avoid common cold or cough medicines that contain opioid agonists (such as codeine or dextromethorphan in certain formulations), as Selincro is contraindicated when taken with any opioid medication.

Q: Why do some sources refer to Selincro as an 'opioid antagonist'?

Nalmefene is formally an opioid receptor modulator. It functions as an antagonist (blocker) at the mu- and delta-opioid receptors, which accounts for its primary action. Due to this significant blocking activity, it is often broadly referred to as an opioid antagonist.

Q: What is the legal status of Selincro 18 mg in different regions?

In all regions where Selincro is approved for the reduction of alcohol consumption, including Europe and Australia, the medicine is classified as a prescription-only medicine.

How should Selincro 18 mg be stored and disposed of?

Storage and Disposal of Selincro 18 mg

The official product information for Selincro specifies the required conditions for product stability, handling, and final disposal.

Requirement Category	Official Regulatory Statement
Storage Conditions	This medicinal product does not require any special storage conditions regarding temperature or environment.
Child Protection	The medicine must be kept out of the sight and reach of children.
Special Handling	The film-coated tablet must not be divided or crushed. The regulatory rationale is that the active substance may cause skin sensitisation upon direct contact.
Shelf Life	The labeled stability period in the original packaging is 3 years.
Disposal	Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Property	Description
Active ingredient	Nalmefene (hydrochloride dihydrate)
Form	Film-coated tablet
Pharmacological class	Opioid System Modulator
Common purpose	Reduction of alcohol consumption
Origin	Semisynthetic

Selincro 18 mg